拓新药业
(301089)
| 流通市值：25.94亿 | | | 总市值：36.28亿 |
| 流通股本：9047.01万 | | | 总股本：1.27亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 92,502,151.55 | 378,343,569.65 | 271,553,589.37 | 181,899,752.24 |
| 营业收入 | 92,502,151.55 | 378,343,569.65 | 271,553,589.37 | 181,899,752.24 |
| 二、营业总成本 | 103,589,969.11 | 434,776,823.75 | 309,371,817.19 | 202,283,727.81 |
| 营业成本 | 69,975,137.75 | 278,547,000.62 | 191,822,036.06 | 125,126,680.21 |
| 税金及附加 | 1,861,332.83 | 8,142,812.21 | 5,745,761.95 | 3,942,785.86 |
| 销售费用 | 2,199,418.14 | 10,408,619.08 | 7,918,604.54 | 5,324,403.79 |
| 管理费用 | 19,638,808.94 | 94,926,371.21 | 72,785,755.57 | 46,993,948.07 |
| 研发费用 | 9,423,934.92 | 42,677,886.02 | 31,165,593.91 | 20,997,456.2 |
| 财务费用 | 491,336.53 | 74,134.61 | -65,934.84 | -101,546.32 |
| 其中:利息费用 | 31,398.68 | 151,035.18 | 119,936.77 | 81,963.7 |
| 其中:利息收入 | 50,867.24 | 896,666.41 | 698,353.03 | 267,986.67 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 489,358.9 | 147,519.18 | 276,136.12 | 755,247.22 |
| 加:投资收益 | 266,751.32 | 4,119,715.12 | 3,035,838.61 | 1,703,047.95 |
| 资产减值损失(新) | -5,943,346.04 | -16,116,367.19 | -7,316,298.7 | -7,316,298.7 |
| 信用减值损失(新) | 1,628,325.21 | -12,187,875.8 | 904,823.12 | 983,104.68 |
| 其他收益 | 1,219,297.78 | 8,712,797.2 | 4,559,553.75 | 3,203,057.75 |
| 四、营业利润 | -13,427,430.39 | -71,757,465.59 | -36,358,174.92 | -21,055,816.67 |
| 加:营业外收入 | 11,921.69 | 151,838.83 | 363,833.31 | 73,868.14 |
| 减:营业外支出 | 44,175.16 | 779,796.05 | 515,280.55 | 449,382.37 |
| 五、利润总额 | -13,459,683.86 | -72,385,422.81 | -36,509,622.16 | -21,431,330.9 |
| 减:所得税费用 | -2,950,022.79 | -2,724,395.11 | -6,348,545.25 | -3,150,781.35 |
| 六、净利润 | -10,509,661.07 | -69,661,027.7 | -30,161,076.91 | -18,280,549.55 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -10,509,661.07 | -69,661,027.7 | -30,161,076.91 | -18,280,549.55 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -10,509,661.07 | -69,661,027.7 | -30,161,076.91 | -18,280,549.55 |
| 扣除非经常损益后的净利润 | -11,998,504.05 | -78,938,143.02 | -35,942,839.18 | -22,207,618.53 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.08 | -0.55 | -0.24 | -0.14 |
| (二)稀释每股收益 | -0.08 | -0.55 | -0.24 | -0.14 |
| 八、其他综合收益 | - | 1,317,652.71 | - | - |
| 归属于母公司股东的其他综合收益 | - | 1,317,652.71 | - | - |
| 九、综合收益总额 | -10,509,661.07 | -68,343,374.99 | -30,161,076.91 | -18,280,549.55 |
| 归属于母公司股东的综合收益总额 | -10,509,661.07 | -68,343,374.99 | -30,161,076.91 | -18,280,549.55 |
| 公告日期 | 2026-04-28 | 2026-03-28 | 2025-10-29 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |